Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Sun Pharma Q1FY27 Profit Jumps 27% on India Growth, Innovative Medicines
Sun Pharmaceutical Industries announced a significant 27 per cent year-on-year jump in consolidated net profit for Q1FY27, reaching Rs 2,894.7 crore, propelled by strong performance in the Indian market and robust growth in its innovative medicine…
Sun Pharma Q1 net rises 27% to ₹2,895 crore
Sun Pharmaceuticals Industries Ltd. for the first quarter ended June 30, 2026 reported a 27% year-n-year growth in consolidated net profit to ₹2,895 crore. Sales income at ₹15,184 crore grew 10.1%. Global Innovative Medicines sales at…
Sun Pharma withdraws multiple eye drop products as precautionary measure
A copy of the confidential letter issued by Sun Pharma Distributors Ltd on July 17 to distributors, accessed by ANI, states that there is a withdrawal of Eye Drops 5ML BKC FREE Lotepred-5ML, etc. “Withdrawal of Product - Depopred2ML…
Amundi Increases Stake in Royalty Pharma PLC $RPRX
Amundi boosted its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 15.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,088,773…
Sun Pharma on track to complete Organon transaction by Q4, says management
Sun Pharmaceutical Industries Ltd expects to complete its $11.75 billion acquisition of US-based Organon in the fourth quarter of financial year 2027, top management with the drugmaker said, after the company shared its financial performance for…
Royalty Pharma PLC $RPRX Shares Sold by California State Teachers Retirement System
California State Teachers Retirement System lowered its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 2.9% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 759,042 shares of the…
Pfizer (NYSE: PFE) Offers Value And Income While Eli Lilly (NYSE: LLY) Bets On Growth In Diverging Pharma Investment Race
Pfizer (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) represent two sharply different investment cases within the pharmaceutical sector, appealing to entirely different types of investors. Pfizer has seen its valuation compress significantly in…
Swiss National Bank Makes New $1.40 Million Investment in Urogen Pharma $URGN
Swiss National Bank purchased a new stake in Urogen Pharma (NASDAQ:URGN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased…
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches (SMMT)
Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically significant PFS but only a favorable trend in OS;…
XLV vs. IHE: Which Healthcare ETF Is the Better Buy?
The State Street Health Care Select Sector SPDR ETF (XLV -0.44%) provides broad healthcare exposure at a lower cost, while the iShares U.S. Pharmaceuticals ETF (IHE -0.91%) offers a concentrated bet on U.S. drugmakers. While both funds target…
CM presents Telangana as safe, strategic investment destination
Chief Minister A. Revanth Reddy has invited industry leaders to invest in Telangana, describing the State as one of the country's most strategic and secure investment destinations. Addressing representatives of the Confederation of Indian Industry…
Uttar Pradesh trade show 2026 aims to boost global manufacturing and exports
With the objective of establishing Uttar Pradesh as a leading hub of global trade, manufacturing and exports, the fourth edition of the Uttar Pradesh International Trade Show (UPITS) will be held from 25 to 29 September at the India Expo Center and…
Nabil Saba on ASCO's New Guideline on Treatment of Thyroid Cancer
This Reading Room is a collaboration between MedPage Today and: Although treatment advances for thyroid cancer have reshaped the management landscape and improved disease control, they have also raised new questions and considerations for…
Janus Henderson Group PLC Has $145.08 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA
Janus Henderson Group PLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 1.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,816,657…
Teva Pharmaceutical Industries Ltd. $TEVA Stake Boosted by Avidity Partners Management LP
Avidity Partners Management LP increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 7.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission.
Receive a Daily briefing on Pharma Industry News
Get Started